Bladder cancer: A patient's guide to the treatment options

Written in association with: Mr Dimitrios Moschonas
Published:
Edited by: Conor Dunworth

In his latest online article, esteemed consultant urological surgeon Mr Dimitrios Moschonas delves into the intricacies of bladder cancer. He explains the diagnosis, the treatments options, and the latest developments in bladder cancer treatment.

 

How quickly does bladder cancer treatment start after a diagnosis?

Let's begin by discussing the most common symptoms of bladder cancer: blood in the urine, recurrent urinary infections, frequency of urination, urgency, or pain on passing urine, even when no infection is found in urine tests by your doctor. Therefore, it's crucial that if you experience any of these symptoms, you promptly see your doctor. They will organise some tests and then refer you to a specialist for further investigations.

This specialist, usually from a urology team, which may involve either a doctor or a specialist nurse, will arrange a couple of tests. These include a CT scan, a detailed scan of the urinary system that detects any abnormalities in the kidneys or bladder, as well as a flexible cystoscopy. This procedure allows for a telescopic examination of your bladder, revealing any abnormal growth in the lining of the urinary system.

As soon as a provisional diagnosis is made through these tests, treatment commences promptly. Time is of the essence in managing bladder cancer, with the principal treatment being transurethral resection of bladder tumor (TURBT). This is typically the first treatment most patients receive after a provisional diagnosis.

TURBT is a minor operation performed with a telescope, removing the cancerous growth and sealing the tissue around it, providing necessary information to understand the extent of the cancer. In patients where the disease is caught in its early stages, TURBT might be the only necessary treatment.

 

How is the treatment for bladder cancer decided?

The treatment for bladder cancer is determined by factors such as the cell type, grade, and stage of the cancer. The cell type, often transitional cell in around 90% of cases, and the stage, indicating the extent of the cancer within the body, play critical roles in deciding the appropriate treatment. Bladder cancer can either be non-muscle invasive, affecting the bladder lining in approximately 80% of cases, or muscle-invasive, affecting around 20% of patients.

 

What is the most common treatment for bladder cancer?

The most common treatment for bladder cancer is transurethral resection of bladder tumour (TURBT), a diagnostic and treatment procedure to remove cancer from the bladder lining. This procedure is performed with a camera within the urethra and the bladder, conducted by a specialist surgeon to ensure complete removal.

Depending on the extent and aggressiveness of the tumour, radical surgery may be necessary. Treatment is typically occurs as a day case in the hospital, and patients may undergo post-surgery chemotherapy to prevent cancer recurrence or progression.

 

What is the latest treatment for bladder cancer?

Recent advancements in bladder cancer treatment include improvements in surgical techniques, visual detection technologies enhancing diagnostic capabilities, and minimally invasive robotic surgery coupled with enhanced recovery protocols. These advancements aim to improve patient experiences, minimise surgical stress, shorten hospital stays, and reduce complication rates, ultimately leading to better functional outcomes and improved cancer prognosis.

 

What is the survival rate of cancer of the bladder?

The survival rate of bladder cancer in the UK has significantly increased over the past 40 years. Survival rates depend on various factors, with approximately 75% of patients surviving for one year or more after diagnosis. Moreover, more than half of patients survive for four to five years or longer after diagnosis.

Early-stage diagnosis significantly improves survival rates, with more than nine in ten patients surviving for one year or more compared to around one in three patients diagnosed at a later stage.

 

Who treats bladder cancer?

Bladder cancer is treated by a multidisciplinary team of healthcare professionals, including specialist urologists, oncologists, radiologists, and pathologists. This team provides comprehensive care tailored to the individual patient, emphasising a patient-centred approach and shared decision-making.

High-quality care involves prompt diagnosis, timely delivery of curative treatments, and excellent patient support to maximise quality of life throughout the treatment process, acknowledging the life-changing nature of bladder cancer treatment.

 

Mr Dimitrios Moschonas is a renowned consultant urological surgeon based in Surrey and London. If you would like to book a consultation with Mr Moschonas, you can do so today via his Top Doctors profile.

By Mr Dimitrios Moschonas
Urology

Mr Dimitrios Moschonas is a renowned consultant urological surgeon, based in Guildford and also practising in London. Thanks to his extensive training, he is experienced in treating many urology problems that affect both men and women. He specialises in the diagnosis and treatment with robotic surgery of prostate and bladder cancer, benign prostatic enlargement, gallstones, kidney stones, recurrent infections, and foreskin issues.  

Mr Moschonas obtained his MD from the University of Patras, Greece in 2003 and undertook specialist training in urology in Athens, Greece. Upon completion of his thesis in 2014, he earned his PhD from the University of Athens. He then moved to the UK where he conducted sub-specialist training in urological oncology at Oxford University Hospitals. Following this, he was selected for a fellowship in robotic pelvic uro-oncology at the Royal Surrey Hospital, where he later became a consultant.  

Mr Moschonas treats patients with innovative and new techniques such as Rezum, for benign prostate hyperplasia. He offers transperineal  fusion-guided targeted prostate biopsies. For patients whose test results indicate there is a higher chance of cancer, he overlays MRI to ultrasound imaging to make an accurate and precise diagnosis. He also treats paediatric patients aged eight or above.  

Mr Moschonas’s NHS base is at the Royal Surrey Trust, where  he is the coordinator of the robotic urology fellowship. His research has been widely published, and he has made presentations at both national and international meetings.
  

   

View Profile

Overall assessment of their patients


  • Related procedures
  • Sexually transmitted infections (STIs)
    Vaginoplasty
    Penis Enlargement (Phalloplasty)
    Adult circumcision
    Laparoscopy
    Urologic Oncology
    Geriatric Urology
    Kidney transplantation
    Phimosis
    Short frenulum
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.